Lilly / Molecular Staging proteomics collaboration.
NEW HAVEN, Conn.--(BUSINESS WIRE)--Jan. 27, 2003--Molecular Staging Inc. (MSI) and Eli Lilly and Company (NYSE:LLY) announced today that they have entered into a clinical proteomics research collaboration.
MSI will use its proprietary clinical proteomics platform and bioinformatics to identify biomarkers in the rapid progression of the deadly condition, sepsis. The goal is to identify opportunities for earlier intervention and improved patient outcomes.
Sepsis is the body's over-reaction to an infection that can lead to organ failure and, ultimately, death. It is one of the most challenging problems in intensive care medicine today and results in more than 200,000 deaths annually in the United States.
"MSI has specifically developed its proteomics solution with a focus on biomarker discovery and validation for clinical research, so we are very pleased to have the opportunity to work with Lilly in this important disease area," said Dr. Stephen Kingsmore, Chief Operating Officer of MSI.
MSI's chip-based clinical proteomics platform enables the study of numerous biologically important proteins simultaneously with excellent sensitivity and the use of very limited amounts of sample. The approach uses MSI's proprietary Rolling Circle Amplification Technology (RCAT(TM)) combined with bioinformatics and clinical knowledge. RCAT is uniquely able to amplify signals tethered to proteins, even low abundance proteins, with the thorough coverage required for effective biomarker discovery.
Molecular Staging Inc. (MSI), a privately held life science company is developing a portfolio of products and services based on their advanced amplification technologies, including products and services that offer a powerful new way to identify individual and multiplexed sets of biomarkers and a rapid, reliable method of generating unlimited DNA from a few cells. MSI technologies, combined with sophisticated bioinformatics, enable a wide range of transformational products and services across multiple health care markets. MSI has exclusively licensed RCAT from Yale University. Additional information about MSI can be found at molecularstaging.com. |
